Long-lasting mechanical heart implanted for the first time in Canada in heart-failure patient

October 12, 2010

In a Canadian first, the Peter Munk Cardiac Centre used a new kind of left ventricular assist device (LVAD) to treat a patient with advanced heart failure. The new device is longer lasting than older generation LVADs and may eliminate the need for a second LVAD - a major drawback with the old technology.

The patient, 61-year-old Marva Lorde of Mississauga, suffered a heart attack in 2007 and underwent several treatments for heart failure - including a 10-day intensive care unit stay, angioplasty and pacemaker implantation -culminating in a cardiac arrest in June 2008.

"I would have died in my sleep if the nurse hadn't checked my heart monitor," says Marva who is at home after receiving her LVAD on July 29, 2010. "Before the LVAD, I had trouble climbing the stairs to my bedroom, but now I'm back to my usual activities, including regular walks, and the stairs don't give me trouble anymore."

Marva's LVAD, known as the DuraHeart, is designed for long-term cardiac support and reduces the risk of complications including strokes, infection and device failure - all of which can happen in mechanical heart devices. The device's central pump is powered by magnetic levitation technology, which means its moving parts are held in place with magnets instead of bearings, eliminating wear and tear on the device. This technology enables blood to flow through the pump smoothly, which extends the life of the device and the life of the patient.

"With access to eight different types of cardiac assist devices, including the Duraheart, we have the most diverse array of circulatory support technology in Canada to best manage patients with end stage heart failure," says Dr. Vivek Rao, Surgical Director of the Heart Transplant Program at the Peter Munk Cardiac Centre (PMCC), Toronto General Hospital.

Heart failure is the most common cause of hospitalization in North American adults and over 50,000 are treated for advanced heart failure annually. Transplantation is the only long-term treatment for end-stage heart failure patients and the long wait times for a matching donor organ make it necessary to find other alternatives.

Marva is currently on the heart transplant waiting list along with 36 other GTA residents, and her LVAD is her lifeline since her weak heart needs support until a new heart becomes available. This "bridge to life" is an innovative approach pioneered in Canada by Dr. Vivek Rao.

"Part of the centre's mandate is to evaluate new technologies such as the Duraheart to help determine which patients are best suited to a specific device," says Dr. Rao who's team has implanted approximately 70 LVADs since 2004, giving hope to many patients and families.

The Duraheart device has been used in patients in Germany and the United States.
-end-
About The Peter Munk Cardiac Centre

The Peter Munk Cardiac Centre is the premier cardiac centre in Canada. Since it opened in 1997, the Centre has saved and improved the lives of cardiac and vascular patients from around the world. Each year, approximately 17,000 patients receive innovative and compassionate care from multidisciplinary teams in the Peter Munk Cardiac Centre, and the Centre trains more cardiologists, cardiovascular surgeons and vascular surgeons than any hospital in Canada. The Centre is based at the Toronto General Hospital and the Toronto Western Hospital - members of University Health Network, which also includes Princess Margaret Hospital. All three sites are research hospitals affiliated with the University of Toronto. For more information please visit www.petermunkcardiaccentre.ca

University Health Network

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.